Welcome to our dedicated page for Shoulder Innovations SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
Shoulder Innovations, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where a quorum of 16,424,584 common shares was present virtually or by proxy. Each share had one vote.
Stockholders elected two Class I directors. Robert Ball received 10,576,791 votes for and 4,236,696 votes withheld, with 1,611,097 broker non-votes. Andrew Hykes received 14,812,410 votes for and 1,077 votes withheld, plus 1,611,097 broker non-votes. Both will serve three-year terms until the 2029 Annual Meeting, subject to earlier death, resignation, or removal.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 16,415,933 votes for, 2 votes against, and 8,649 abstentions, and no broker non-votes.
SHOULDER INNOVATIONS, INC. director and Chief Operating Officer Matthew Fraser Ahearn reported open-market sales of 20,000 shares of Common Stock. The trades on June 12 and 15, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, at weighted-average prices ranging from $17.98 to $19.71 per share. Following these transactions, he directly holds 269,176 shares of the company’s common stock.
Shoulder Innovations reported strong top-line growth for the quarter ended March 31, 2026. Net revenue rose to $16.7 million, up 64.9% from $10.1 million a year earlier, driven by more implant systems sold and a higher average selling price, while gross margin improved slightly to 77.7%.
Higher spending to scale the business widened the net loss to $8.4 million from $4.7 million, and Adjusted EBITDA was $(7.0) million. The company ended the quarter with $108.5 million in cash, cash equivalents and marketable securities and $15.0 million of term debt, after using $12.4 million of cash in operating activities. Management highlighted rapid procedure growth, ongoing product and robotics development, an active patent dispute with Catalyst Orthoscience, and a new headquarters lease to support future expansion.
Shoulder Innovations reported strong first quarter 2026 growth but wider losses. Net revenue rose 65% to $16.7 million, driven by higher implant volumes and more customers, and gross margin improved to 77.7% from 76.9%.
Selling, general and administrative expenses increased 73% to $18.2 million and research and development expenses rose 137% to $3.8 million, reflecting commercial expansion and product development. This led to an operating loss of $9.0 million and net loss of $8.4 million, both roughly double the prior-year period. Adjusted EBITDA loss was $7.0 million.
Management raised full-year 2026 net revenue guidance to a range of $65 million to $68 million, implying approximately 37% to 44% growth over 2025. The company ended March 31, 2026 with $108.5 million in cash, cash equivalents and marketable securities, providing resources to support its growth strategy.
Shoulder Innovations, Inc. amendment to a Schedule 13G/A reports beneficial ownership positions held by cultivate(MD) Holdings, LLC and four associated reporting persons. The filing states 15,936 shares held by Cultivate MD Capital Fund I, LLC and cites 20,647,526 shares outstanding as of March 3, 2026 used to calculate percentages. Individual reported beneficial amounts include 300,939 for David L. Blue (1.5%), 317,137 for Matthew F. Ahearn (1.5%), 767,809 for Robert J. Ball (3.6%), and 155,052 for R. Sean Churchill (0.8%).
SHOULDER INNOVATIONS, INC. director and CEO Robert Joseph Ball exercised stock options to acquire 10,000 shares of Common Stock at $2.4804 per share. Following the transaction, he directly holds 300,018 common shares.
His stock option position stands at 309,756 options after the exercise, with these options expiring on May 17, 2033. A footnote explains that his current share count includes 4,400 shares received from Cultivate MD Capital Fund I, LLC and 6,752 shares from Genesis Investment Holdings as in-kind distributions, in addition to the 278,866 shares previously reported as directly owned.
Shoulder Innovations, Inc. is holding its 2026 virtual annual stockholder meeting on June 26, 2026 at 3:00 p.m. Eastern Time. Stockholders of record as of April 27, 2026, holding 20,727,949 common shares, may vote on two proposals: electing two Class I directors and ratifying Deloitte & Touche LLP as independent auditor for 2026.
The proxy details board structure, committee memberships, director compensation, related‑party transactions, and 2025 executive pay, including salary, stock options, and cash bonuses under the company’s performance‑based incentive plan.
Shoulder Innovations, Inc. announced the full commercial launch of its InSet™ I-135RFX Humeral Stem, expanding its I-Series shoulder implant portfolio. This launch follows a successful limited market release and FDA 510(k) clearance for additional fracture indications.
The InSet™ I-135RFX can now be used in primary, revision, and fracture total shoulder arthroplasty procedures, in both anatomic and reverse configurations. It joins the InSet™ 95 and InSet™ 70, launched in 2024 and 2025, and is built on the company’s lateral-lateral implant philosophy aimed at reducing complications and improving post-operative range of motion.